Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 11/20 | 0.46 |
| ▸ | CA2 | P00918 | 11/20 | 0.46 |
| ▸ | CA12 | O43570 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12122306 | 0.90 | CA1 (0.46) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL12972387 | 0.90 | TDP1 (0.47) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28301448 | 0.89 | TDP1 (0.59) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL12972389 | 0.88 | TDP1 (0.42) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL21229156 | 0.85 | TDP1 (0.50) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL7352046 | 0.85 | TDP1 (0.58) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1897482 | 0.84 | CA1 (0.47) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL18970801 | 0.83 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL5209649 | 0.83 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| Hydrochloric Acid SCHEMBL29948784 | 0.83 | TDP1 (0.56) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115536576-A | Sulfonylbenzamide derivatives, conjugates thereof, preparation methods and applications of derivatives and conjugates | 江苏恒瑞医药股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-9468635-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| US-9468635-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| CN-103415507-B | As the 3-amino-pyridine class of GPBAR1 agonist | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-02 | — | — | CN | disclosed |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2015-05-07 | — | — | US | disclosed |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2015-05-07 | — | — | US | disclosed |
| US-8946279-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2015-02-03 | — | — | US | disclosed |
| US-7572915-B2 | 4-[(3-methylphenyl)amino]-6-(methylsulfonyl)-3-quinolinecarboxamide; asthma, COPD, allergic rhinitis, or rheumatoid arthritis in a human | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-7566786-B2 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-07-28 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | TDP1 4271/4885MEN1 1626/4885GAA 4803/4885 |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | TDP1 4502/4885MEN1 369/4885GAA 1806/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TDP1 4714/4885MEN1 3001/4885GAA 2534/4885 |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NR3C2, REN, MC2R | TDP1 4723/4885MEN1 344/4885GAA 4861/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TDP1 70/4885MEN1 2927/4885GAA 477/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TDP1 70/4885MEN1 2927/4885GAA 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.